Alys Pharmaceuticals
Founded 2024 · $100.0M raised
- Founded
- 2024
- Website
- alyspharma.com
- Total Funding
- $100.0M
- Last Round
- $100.0M SeedFeb 2024
- Rounds
- 1
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
Alys Pharmaceuticals is a pioneering force in immuno-dermatology, poised to redefine the treatment landscape with cutting-edge science and a robust R&D-centric multi-platform pipeline. Launched in February 2024, the company was formed through the strategic aggregation of six asset-centric biotech companies backed by Medicxi, and has received a total of $100M in financing from Medicxi. Alys is focused on transforming the treatment paradigm across dermatological indications ranging from atopic dermatitis to emerging categories like vitiligo, alopecia areata, and chronic spontaneous urticaria.
Summary
Alys Pharmaceuticals is a Biotech company, founded in 2024. It has raised $100.0M in total across 1 round, most recently a $100.0M Seed round in Feb 2024. Investors include Medicxi.
Funding History
Feb 2024
Investors
Similar Companies
Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...
Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intellig...
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/alys-pharmaceuticals"><img src="https://indexed.vc/api/badge/company/alys-pharmaceuticals" alt="Alys Pharmaceuticals on Indexed.vc" width="260" height="76" /></a>